FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

rraogto,	, 2.0. 200 .0	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPRO	JVAL
OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

					0.		55(11)	J. 1110		50										
1. Name and Address of Reporting Person* MCKENZIE DIANA					VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Ch	5. Relationship of Repor (Check all applicable) X Director			10% Ov)wner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023										Officer (give title below)		Other (s below)	pecify	
INCORPORATED 50 NORTHERN AVENUE					4. If										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) BOSTON MA 02210				Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication																
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Tab	le I - No	n-Deriv	ative	Sec	curitie	s Ac	quired,	Dis	posed o	of, or	Ben	eficial	ly Owned	d				
Date					Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dis		Dispose	ecurities Acquired (A) o posed Of (D) (Instr. 3, 4 a			Benefic Owned	es ially Following	Form (D) or		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount		(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common	Stock			05/01	/2023		D		1,449		D	(1)	1,435			D				
Common	Stock			05/01	/2023		A		1,168(2)		A	\$0.0	0 2,	603		D				
Common Stock															2	207			Held in Trust	
		T							uired, D s, option			,		,	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code (8)		ı of		6. Date Exercisa Expiration Date (Month/Day/Yea		•	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Own S For Ily Dire or I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	0 N	Amount or Number of Shares						
Deferred Stock	(3)	05/01/2023			A		1,449		(3)		(3)	Com		1,449	(1)	4,566.5	21	D		

Explanation of Responses:

- 1. Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units.
- 2. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- 3. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

Remarks:

/s/ Christiana Stevenson, 05/03/2023 Attorney-in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.